Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$712M |
| 2 |
PepsiCo
PEP
|
+$669M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$635M |
| 4 |
Walmart Inc
WMT
|
+$544M |
| 5 |
Palantir
PLTR
|
+$538M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.34B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.65B |
| 3 |
Tesla
TSLA
|
+$1.45B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.01B |
| 5 |
Apple
AAPL
|
+$833M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.48% |
| 2 | Financials | 7.27% |
| 3 | Consumer Discretionary | 6.82% |
| 4 | Communication Services | 5.06% |
| 5 | Healthcare | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
DXP Enterprises
DXPE
$2.49B
| $2.33M | ﹤0.01% |
19,591
-7,707
| -28% | -$861K |
|
2752
Vitamin Cottage Natural Grocers
NGVC
$757M
| $2.33M | ﹤0.01% |
58,249
+34,098
| +141% | +$1.32M |
|
2753
CALL
TeraWulf
WULF
$9.16B
| $2.33M | ﹤0.01% |
204,000
| – | – |
|
2754
Nelnet
NNI
$4.98B
| $2.33M | ﹤0.01% |
18,578
-7,490
| -29% | -$937K |
|
2755
Werner Enterprises
WERN
$2.26B
| $2.33M | ﹤0.01% |
88,483
-412,903
| -82% | -$11.6M |
|
2756
Anavex Life Sciences
AVXL
$260M
| $2.33M | ﹤0.01% |
261,280
-22,979
| -8% | -$233K |
|
2757
PAR Technology
PAR
$718M
| $2.32M | ﹤0.01% |
58,681
-41,741
| -42% | -$2.31M |
|
2758
Hallador Energy
HNRG
$666M
| $2.32M | ﹤0.01% |
118,609
+27,111
| +30% | +$466K |
|
|
AAT
2759
American Assets Trust
AAT
$1.46B
| $2.32M | ﹤0.01% |
114,158
-17,364
| -13% | -$350K |
|
2760
Ouster
OUST
$2.69B
| $2.31M | ﹤0.01% |
85,523
-17,817
| -17% | -$497K |
|
2761
Artivion
AORT
$1.35B
| $2.31M | ﹤0.01% |
54,616
-19,520
| -26% | -$736K |
|
2762
Alpha and Omega Semiconductor
AOSL
$948M
| $2.31M | ﹤0.01% |
82,597
-8,625
| -9% | -$239K |
|
2763
Independent Bank Corp
IBCP
$796M
| $2.31M | ﹤0.01% |
74,553
-13,126
| -15% | -$424K |
|
|
SMLR
2764
DELISTED
Semler Scientific
SMLR
| $2.3M | ﹤0.01% |
76,675
+349
| +0.5% | +$12K |
|
2765
ARS Pharmaceuticals
SPRY
$521M
| $2.3M | ﹤0.01% |
228,569
-393,666
| -63% | -$5.65M |
|
|
AVDL
2766
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.3M | ﹤0.01% |
150,373
-32,485
| -18% | -$423K |
|
2767
CALL
Incyte
INCY
$24.5B
| $2.29M | ﹤0.01% |
+27,000
| New | +$2.13M |
|
|
2768
PUT
Incyte
INCY
$24.5B
| $2.29M | ﹤0.01% |
+27,000
| New | +$2.13M |
|
2769
Albany International
AIN
$2.16B
| $2.29M | ﹤0.01% |
42,943
-16,254
| -27% | -$1.03M |
|
|
BOW
2770
Bowhead Specialty Holdings
BOW
$1.11B
| $2.28M | ﹤0.01% |
84,492
-9,411
| -10% | -$295K |
|
2771
Hilltop Holdings
HTH
$2.28B
| $2.28M | ﹤0.01% |
68,328
-84,707
| -55% | -$2.76M |
|
2772
Porch Group
PRCH
$1.74B
| $2.28M | ﹤0.01% |
136,071
-32,787
| -19% | -$503K |
|
2773
ImmunityBio
IBRX
$7.6B
| $2.28M | ﹤0.01% |
927,687
+87,793
| +10% | +$226K |
|
2774
Ziff Davis
ZD
$1.99B
| $2.28M | ﹤0.01% |
59,808
-27,222
| -31% | -$953K |
|
2775
Corvus Pharmaceuticals
CRVS
$1.12B
| $2.28M | ﹤0.01% |
309,152
-34,374
| -10% | -$176K |
|
Similar funds
Barclays's Q3 2025 Portfolio in Review
As of Q3 2025, Barclays held 5,800 positions worth $461B, up 5.7% from $436B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays's Q3 2025 filing shows 615 new, 1,596 increased, 2,751 reduced and 340 closed positions. Its largest new stake was Paramount Skydance Corp: 13,646,704 shares worth $258M. The largest sale was NVIDIA, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Barclays's largest Q3 2025 buy was Paramount Skydance Corp: 13,646,704 shares worth $258M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q3 2025, an estimated $712M increase.
- Barclays's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $2.34B.
- Barclays fully exited Blueprint Medicines in Q3 2025, selling an estimated $200M.
- Barclays's ten largest holdings make up 40% of its $461B portfolio in Q3 2025.
- Barclays opened 615 new positions and closed 340 in Q3 2025.
- Barclays's portfolio value rose 5.7% quarter-over-quarter to $461B.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.